Digital medicine Take 2: Proteus Digital Health, Otsuka resubmit FDA application
After more than one year since the FDA sent Proteus Digital Health and Otsuka back to the drawing board with a complete response letter on their joint initiative for a digital medicine to track the body's response to a drug, they've resubmitted the NDA